

Yong Fan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1919/yong-fan-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

194
citations

8
h-index

13
g-index

24
ext. papers

362
ext. citations

4.5
avg, IF

3.73
L-index

#	Paper	IF	Citations
21	Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.. <i>Drugs of Today</i> , 2022 , 58, 23-32	2.5	1
20	Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients with Advanced Non-Small Cell Lung Cancer and Pre-existing Interstitial Lung Diseases: A Systematic Review and Meta-Analysis.. <i>Chest</i> , 2022 ,	5.3	1
19	Towards a Better Implementation of Treat-to-Target Strategy in Rheumatoid Arthritis: A Comparison of Two Real-World Cohorts.. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
18	Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	11
17	Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model. <i>Physiological Research</i> , 2021 , 70, 213-226	2.1	8
16	Mortality in patients with primary Sjögrens syndrome: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021 , 60, 4029-4038	3.9	3
15	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 633032	5.3	12
14	Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. <i>European Journal of Internal Medicine</i> , 2021 , 87, 20-28	3.9	7
13	Identification of exosome miRNAs in bronchial epithelial cells after PM2.5 chronic exposure. <i>Ecotoxicology and Environmental Safety</i> , 2021 , 215, 112127	7	5
12	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021 , 15, 33-42	12	14
11	Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 175-191	5.3	8
10	Predicting lupus low disease activity state and remission in SLE: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1083-1089	5.1	0
9	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
8	Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020 , 59, 3400-3407	3.9	4
7	Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. <i>Autoimmunity Reviews</i> , 2020 , 19, 102687	13.6	13
6	Systemic lupus erythematosus: year in review 2019. <i>Chinese Medical Journal</i> , 2020 , 133, 2189-2196	2.9	5
5	Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 123	5.7	10

4	Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1048-1054	2.4	69
3	Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. <i>Clinical Rheumatology</i> , 2019 , 38, 2765-2776	3.9	11
2	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 623-632	2.2	5
1	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. <i>International Journal of Medical Sciences</i> , 2017 , 14, 820-828	3.7	6